🧬 FDA expands options for rare disease trials
El Salvador Hosts World-First Robotic Eye Surgery 🌎
A pioneering RNA therapy being developed in Melbourne could transform the treatment of lupus, offering new hope to thousands of Australians living with the chronic autoimmune disease.
What Mexico’s EU Deal Means for Medtech 🌐
Friday 24 October 2025 Latin America seeks to quadruple its participation in clinical trials Clinical research is essential to developing new treatment options, improving diagnostic tools, and advancing disease prevention. These efforts not only extend life expectancy and reduce mortality rates but also contribute significantly to the social and economic development of nations. Yet despite its po
🧬 LatAm Unifies Regulations Across Eight Nations
We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below. The cookies that are categorised as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... Necessary cookies are required to enable the basic features of this site, such
🧬 How This Gene Therapy Got FDA Fast Track Status
We use cookies and other tracking technologies to improve your browsing experience on our website, to show you personalized content and targeted ads, to analyze our website traffic, and to understand where our visitors are coming from. Error! We're sorry, but the page you were looking for doesn't exist. LEXINGTON, Mass., Oct. 6, 2025 /PRNewswire/ -- Hyalex Orthopaedics, a privately held medi
🌍 Colombia Joins Global Regulators: What Changes Ahead?
🧬 Fast Track opens new doors for rare diseases
Some of the world’s largest funders of medical research have today committed, through the signature of a joint statement, to implement WHO standards to strengthen clinical trial systems and ensure that research better serves patients and communities. The statement sets out measures to integrate clinical trials into sustainable national infrastructure, improve trial design, ensure that trial populations are representative, and embed best practices on transparency, data management and public engagement.
📈 What Do 14 Device Approvals Mean for LatAm?
🌍 Can Latin America Outpace U.S. in Trial Speed?
🏥 Inside the Hospital Powering On-Demand Isotopes